Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.61 |
| ▸ | DRD2 | P14416 | 3/20 | 0.61 |
| ▸ | DRD3 | P35462 | 2/20 | 0.61 |
| ▸ | JAK2 | O60674 | 2/20 | 0.54 |
| ▸ | JAK3 | P52333 | 2/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | CCR2 | P41597 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154970 | 0.92 | MCHR1 (0.56) | DRD4DRD2DRD3ROCK2MCHR1 | |
| SCHEMBL6153691 | 0.88 | MCHR1 (0.60) | DRD4DRD2DRD3MCHR1ACHE | |
| SCHEMBL6154470 | 0.80 | KCNH2 (0.65) | DRD2ROCK2ROCK1 | |
| SCHEMBL6153437 | 0.80 | ROCK2 (0.60) | DRD4DRD2JAK2JAK3ROCK2 | |
| SCHEMBL6153423 | 0.80 | MCHR1 (0.62) | DRD4DRD2DRD3MCHR1ACHE | |
| SCHEMBL6153759 | 0.79 | MCHR1 (0.61) | DRD4DRD2DRD3MCHR1ACHE | |
| SCHEMBL6154946 | 0.78 | LTA4H (0.52) | DRD4DRD2DRD3JAK2JAK3 | |
| SCHEMBL6154307 | 0.78 | ROCK2 (0.47) | DRD2ROCK2GAAROCK1MCHR1 | |
| SCHEMBL6154310 | 0.78 | ROCK2 (0.47) | DRD2ROCK2GAAROCK1MCHR1 | |
| SCHEMBL6154103 | 0.78 | MCHR1 (0.51) | DRD4DRD2DRD3JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | DRD4 3929/4885DRD2 3058/4885DRD3 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.